Literature DB >> 10995876

eNOS expression is associated with the estrogen and progesterone receptor status in invasive breast carcinoma.

M Vakkala1, P Paakko, Y Soini.   

Abstract

In this study we investigated the immunohistochemical expression of eNOS and nNOS in 80 invasive breast carcinomas. Since NO is known to influence apoptosis and angiogenesis we also determined the apoptotic index of the tumor cells by the TUNEL method and tumor angiogenesis by immunostaining the sections with FVIII-related antigen and assessing the number of positively stained vessels. Respectively, 65% and 11% of the cases expressed cytoplasmic positivity for eNOS and nNOS. The mean apoptotic index of the tumors was 0.60%. eNOS or nNOS expression did not associate with the apoptotic index (p=0.36 and p=0.58, respectively). Cases with a positive estrogen or progesterone receptor status were significantly more often eNOS positive than receptor negative cases (p=0.012 and p=0.015, respectively). No association was found between the estrogen or progesterone receptor status and nNOS expression. Neither eNOS nor nNOS expression was associated with vascular density, tumor grade or the TNM status of the tumors. The results show that eNOS and nNOS are expressed in breast carcinomas possibly contributing to their NO synthesis. No association with apoptosis or angiogenesis was detected. eNOS expression was, however, associated with the positive estrogen and progesterone receptors status suggesting that its synthesis might be regulated by hormonal stimulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10995876     DOI: 10.3892/ijo.17.4.667

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  7 in total

1.  Immunohistochemical study of the angiogenetic network of VEGF, HIF1α, VEGFR-2 and endothelial nitric oxide synthase (eNOS) in human breast cancer.

Authors:  Maria Kafousi; Thomas Vrekoussis; Eleftheria Tsentelierou; Kitty Pavlakis; Iordanis Navrozoglou; Vassilios Dousias; Elias Sanidas; Dimitrios Tsiftsis; Vassilios Georgoulias; Efstathios N Stathopoulos
Journal:  Pathol Oncol Res       Date:  2011-06-14       Impact factor: 3.201

Review 2.  NO to breast: when, why and why not?

Authors:  Shehla Pervin; Gautam Chaudhuri; Rajan Singh
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

Review 3.  Cancer cell metabolism and the modulating effects of nitric oxide.

Authors:  Ching-Fang Chang; Anne R Diers; Neil Hogg
Journal:  Free Radic Biol Med       Date:  2014-11-22       Impact factor: 7.376

4.  Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.

Authors:  G M K Tse; F C Wong; A K H Tsang; C S Lee; P C W Lui; A W I Lo; B K B Law; R A Scolyer; R Z Karim; T C Putti
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

5.  Evaluation of iNOS Expression in Esophageal Cancer Patients.

Authors:  Romina Barani; Gholamreza Motalleb; Hossein Maghsoudi
Journal:  Gastrointest Tumors       Date:  2016-03-17

Review 6.  Anti-cancer therapies that utilize cell penetrating peptides.

Authors:  Benjamin G Bitler; Joyce A Schroeder
Journal:  Recent Pat Anticancer Drug Discov       Date:  2010-06       Impact factor: 4.169

Review 7.  Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities.

Authors:  Caiguo Zhang; Fan Zhang
Journal:  Protein Cell       Date:  2014-12-06       Impact factor: 14.870

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.